Zanidip 20 mg Norge - norsk - Statens legemiddelverk

zanidip 20 mg

recordati ireland limited - lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg

Lercanidipine Orion 20 mg Norge - norsk - Statens legemiddelverk

lercanidipine orion 20 mg

orion corporation - espoo - lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg

Lercanidipine Orion 10 mg Norge - norsk - Statens legemiddelverk

lercanidipine orion 10 mg

orion corporation - espoo - lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg

Cipramil 10 mg Norge - norsk - Statens legemiddelverk

cipramil 10 mg

h. lundbeck a/s - citalopramhydrobromid - tablett, filmdrasjert - 10 mg

Cipramil 20 mg Norge - norsk - Statens legemiddelverk

cipramil 20 mg

h. lundbeck a/s - citalopramhydrobromid - tablett, filmdrasjert - 20 mg

Enalapril/Lercanidipine Krka 20 mg / 10 mg Norge - norsk - Statens legemiddelverk

enalapril/lercanidipine krka 20 mg / 10 mg

krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg

Enalapril/Lercanidipine Krka 10 mg / 10 mg Norge - norsk - Statens legemiddelverk

enalapril/lercanidipine krka 10 mg / 10 mg

krka sverige ab - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg

Zanipress 10 mg / 10 mg Norge - norsk - Statens legemiddelverk

zanipress 10 mg / 10 mg

recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 10 mg / 10 mg

Zanipress 20 mg / 10 mg Norge - norsk - Statens legemiddelverk

zanipress 20 mg / 10 mg

recordati ireland limited - enalaprilmaleat / lerkanidipinhydroklorid - tablett, filmdrasjert - 20 mg / 10 mg

Inrebic Den Europæiske Union - norsk - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.